Tirzepatide 60mg

Tirzepatide (60 mg) is a synthetic lipidated peptide composed of 39 amino acids with a C20 fatty diacid moiety, manufactured for non-clinical laboratory investigation. The tirzepatide peptide is produced via controlled synthesis and purification to ensure consistency across experimental workflows. Researchers who order tirzepatide peptide in this higher-mass format often use it for extended protocols or multi-phase research designs.

The peptide has a molecular weight of approximately 4.8 kDa and is supplied as a high-purity (≥98%) lyophilized powder in a sealed research-grade vial. This presentation supports structural stability, accurate reconstitution, and reliable handling for in vitro and preclinical research applications.

Within the scientific literature, tirzepatide has been examined for its interaction with biological systems associated with energy utilization, glucose-related processes, and broader metabolic regulation. These investigations are conducted exclusively in controlled research environments and do not involve clinical or therapeutic evaluation.

• High-purity tirzepatide peptide suitable for advanced laboratory research
• Supplied as a 60 mg lyophilized powder in a sealed research-grade vial
• Verified identity and purity testing to support reproducibility
• Examined in experimental models of metabolic and endocrine function
• Compatible with in vitro and preclinical laboratory protocols
• Stable formulation under recommended storage and handling conditions
• Designed for standard laboratory reconstitution procedures
• For laboratory research use only.

Tirzepatide is being studied in laboratory models for its involvement in metabolic regulation and nutrient-response signaling. Research investigations examine its interactions with the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor systems to explore peptide-driven metabolic behavior.

Applications focus on system-level observation of energy balance and glucose handling under controlled experimental conditions. These studies generate structured laboratory data intended to inform future research planning rather than therapeutic interpretation.

Experimental evaluations of the tirzepatide peptide commonly use nanomolar to micromolar concentrations in cell-based assays. In preclinical models, weight-adjusted dosing protocols may be applied according to the study design and analytical endpoints.

Observed effects are recorded as changes in metabolic markers, biological activity, or other measurable laboratory parameters relevant to the selected research model. All reported values remain specific to the experimental context.

All dosing references are provided solely to support research methodology and experimental reproducibility.

Store the product in its lyophilized form at –20 °C or below, protected from light and moisture. Reconstituted solutions should be prepared using sterile laboratory techniques, stored at 2–8 °C, and used within 72 hours unless stability data indicate otherwise. Avoid repeated freeze–thaw cycles to preserve peptide integrity. Laboratories that buy tirzepatide peptide must adhere to institutional documentation and handling standards. Standard laboratory safety procedures must be observed at all times.

References

https://www.pnas.org/doi/10.1073/pnas.2116506119

https://pmc.ncbi.nlm.nih.gov/articles/PMC9438179/

https://pmc.ncbi.nlm.nih.gov/articles/PMC9149770/

https://pmc.ncbi.nlm.nih.gov/articles/PMC9396640/

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.